Tocolysis: Current controversies, future directions

Current Opinion in Investigational Drugs

Volumn 5, Issue 4, 2004, Pages 424-429

  Cole, Stephen ^a   Smith, Roger ^a   Giles, Warwick ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Calcium channel blockers; Clinical trials; Oxytocin; Preterm labor; Prostaglandins; Tocolysis

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; MAGNESIUM SULFATE; OXYTOCIN RECEPTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UTERUS SPASMOLYTIC AGENT;

ANIMAL; DRUG ANTAGONISM; FEMALE; HUMAN; METHODOLOGY; PREGNANCY; PREMATURE LABOR; REVIEW; TOCOLYSIS;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MAGNESIUM SULFATE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; RECEPTORS, OXYTOCIN; SYMPATHOMIMETICS; TOCOLYSIS; TOCOLYTIC AGENTS;

EID: 3042571668     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Nassar N, Sullivane EA: Australia's mothers and babies 1999. Australian Institute for Health and Welfare, National Perinatal Statistics Unit, Sydney, Australia (2001): Perinatal Statistics Series no 11.
2. Martin JA, Hamilton BE, Ventura SJ, Menacker F, Park MM: Births: Final data for 2000. National vital statistics reports. National Center for Health Statistics, Hyatsville, MD, USA (2002).
3. Copper RL, Goldenberg RL, Creasy RK, DuBard MB, Davis RO, Entman SS, Iams JD, Cliver SP: A multicenter study of preterm birth weight and gestational age-specific neonatal mortality. Am J Obstet Gynecol (1993) 168(1 Pt 1):78-84.
4. Lumley J: The epidemiology of preterm birth. Bailleres Clin Obstet Gynaecol (1993) 7(3):477-498.
5. Arias F, Tomich P: Etiology and outcome of low birth weight and preterm infants. Obstet Gynecol (1982) 60(3):277-281.
6. Joseph KS, Kramer MS, Marcoux S, Ohlsson A, Wen SW, Allen A, Platt R: Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994. N Engl J Med (1998) 339(20):1434-1439.
7. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A: Tocolytics for preterm labor: A systematic review. Obstet Gynecol (1999) 94(5 Pt 2):869-877.
8. Treatment of preterm labor with the β-adrenergic agonist ritodrine. The Canadian Preterm Labor Investigators Group. N Engl J Med (1992) 327(5):308-312.
9. Crowley P: Prophylactic corticosteroids for preterm birth (Cochrane Review). Cochrane Database Syst Rev (2000) 2:CD000065.
10. Duley LMM: Guideline No 1(B): Tocolytic drugs for women in preterm labour. Royal College of Obstetricians and Gynaecologists, London, UK (2002).
11. Steer CM, Petrie RH: A comparison of magnesium sulfate and alcohol for the prevention of premature labor. Am J Obstet Gynecol (1977) 129(1):1-4.
12. Cotton DB, Strasser HT, Hill LM, Schifrin BS, Paul RH: Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. J Reprod Med (1984) 29(2):92-97.
13. Cox SM, Sherman ML, Leveno KJ: Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol (1990) 163(3):767-772.
14. Crowther CA, Hiller JE, Doyle LW: Magnesium sulfate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev (2002) 4:CD001060.
15. Hill WC: Risks and complications of tocolysis. Clin Obstet Gynecol (1995) 38(4):725-745.
16. King JF, Flenady VJ, Papatsonis DNM, Dekker GA, Carbonne B: Calcium channel blockers for inhibiting preterm labour (Cochrane review). In: The Cochrane Library. Oxford, Update Software (2002):2.
17. Oei SG, Mol BW, de Kleine MJ, Brolman HA: Nifedipine versus ritodrine for suppression of preterm labor; a meta-analysis. Acta Obstet Gynaecol Scand (1999) 78(9):783-788.
18. The Worldwide Atosiban versus β-Agonists Study Group: Effectiveness and safety of the oxytocin antagonist atosiban versus β-adrenergic agonists in the treatment of preterm labour. Br J Obstet Gynaecol (2001) 108(2):133-142.
19. Arias F: Pharmacology of oxytocin and prostaglandins. Clin Obstet Gynecol (2000) 43(3):455-468.
20. MacKenzie LW, Garfield RE: Hormonal control of gap junctions in the myometrium. Am J Physiol (1985) 248(3 Pt 1):C296-C308.
21. Bennett P, Allport V, Loudon J, Elliott C: Prostaglandins, the fetal membranes and the cervix. Front Horm Res (2001) 27:147-164.
22. Slater D, Allport V, Bennett P: Changes in the expression of the type-2 but not the type-1 cyclo-oxygenase enzyme in chorion-decidua with the onset of labour. Br J Obstet Gynaecol (1998) 105(7):745-748.
23. Dudley DK, Hardie MJ: Fetal and neonatal effects of indomethacin used as a tocolytic agent. Am J Obstet Gynecol (1985) 151(2):181- 184.
24. Moise KJ Jr, Huhta JC, Sharif DS, Ou CN, Kirshon B, Wasserstrum N, Cano L: Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med (1988) 319(6):327-331.
25. Eronen M, Pesonen E, Kurki T, Ylikorkala O, Hallman M: The effects of indomethacin and a β-sympathomimetic agent on the fetal ductus arteriosus during treatment for premature labor: A randomized double-blind study. Am J Obstet Gynecol (1991) 164(1 Pt 1):141-146.
26. Respondek M, Weil SR, Huhta JC: Fetal echocardiography during indomethacin treatment. Ultrasound Obstet Gynecol (1995) 5(2):86-89.
27. Ben-David Y, Hallak M, Rotschild A, Sorokin Y, Auslender R, Abramovici H: Indomethacin and fetal ductus arteriosus: Complete closure after cessation of prolonged therapeutic course. Fetal Diagn Ther (1996) 11(5):341-344.
28. Premature closure of the fetal ductus arteriosus after maternal use of non-steroidal anti-inflammatory drugs. Adverse Drug Reactions Advisory Committee. Med J Aust (1998) 169(5):270-271.
29. Moise KJ Jr: Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol (1993) 168(5):1350-1353.
30. Hammerman C, Glaser J, Kaplan M, Schimmel MS, Ferber B, Eidelman AI: Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Pediatrics (1998) 102(5):E56.
31. Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI: Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med (1993) 329(22):1602-1607.
32. Coceani F, Ackerley C, Seidlitz E, Kelsey L: Function of cyclooxygenase-1 and cyclo-oxygenase-2 in the ductus arteriosus from foetal lamb: Differential development and change by oxygen and endotoxin. Br J Pharmacol (2001) 132(1):241-251.
33. Guerguerian A-M, Hardy P, Bhattacharya M, Olley P, Clyman RI, Fouron J-C, Chemtob S: Expression of cyclooxygenases in ductus arteriosus of fetal and newborn pigs. Am J Obstet Gynecol (1998) 179(6 Pt 1):1618-1626.
34. Olson DM, Mijovic JE, Zaragoza DB, Cook JL: Prostaglandin endoperoxidase H synthase type 1 and type 2 messenger ribonucleic acid in human fetal tissues throughout gestation and in the newborn infant. Am J Obstet Gynecol (2001) 184(2):169-174.
35. Patrono C, Patrignani P, Garcia Rodriguez LA: Cyclooxygenaseselective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs. J Clin Invest (2001) 108(1):7-13.
36. Doret M, Mellier G, Benchaib M, Piacenza JM, Gharib C, Pasquier JC: In vitro study of tocolytic effect of rofecoxib, a specific cyclooxygenase 2 inhibitor. Comparison and combination with other tocolytic agents. Br J Obstet Gynaecol (2002) 109(9):983-988.
37. McWhorter J, Carlan S, O'Leary T: Rofecoxib versus magnesium sulfate to arrest preterm labor: A randomized double-blind trial. Obstet Gynecol (2002) 99(Suppl):Abs 2S.
38. Groom KM, Shennan AH, Jones BA, Seed P, Bennett P: TOCOX - A randomised double blind placebo controlled trial to assess the safety of the use of rofecoxib (a COX-2 specific PG inhibitor) for the prevention of preterm delivery in women at high risk. J Soc Gyn Invest (2003) 10(Suppl)307A:Abs 654.
39. Schwarz MK, Page P: Preterm labour: An overview of current and emerging therapeutics. Curr Med Chem (2003) 10(15):1441-1468.
40. Fuchs A, Goeschen K, Husslein P, Rasmussen AB, Fuchs F: Oxytocin and initiation of human parturition. III. Plasma concentrations of oxytocin and 13,14-dihydro-15-keto-prostaglandin F2α in spontaneous and oxytocin-induced labor at term. Am J Obstet Gynecol (1983) 147(5):497-502.
41. Goodwin TM, Zograbyan A: Oxytocin receptor antagonists. Update. Clin Perinatol (1998) 25(4):859-871.
42. Grigsby PL, Poore KR, Hirst JJ, Jenkin G: Inhibition of premature labor in sheep by a combined treatment of nimesulide, a prostaglandin synthase type 2 inhibitor, and atosiban, an oxytocin receptor antagonist. Am J Obstet Gynecol (2000) 183(3):649-657.
43. Katz Z, Lancet M, Yemini M, Mogilner BM, Feigl A, Ben Hur H: Treatment of premature labor contractions with combined ritodrine and indomethacine. Int J Gynaecol Obstet (1983) 21(4):337-342.
44. Gamissans O, Canas E, Cararach V, Ribas J, Puerto B, Edo A: A study of indomethacin combined with ritodrine in threatened preterm labor. Eur J Obstet Gynecol Reprod Biol (1978) 8(3):123-128.
45. da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M: Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. Am J Obstet Gynecol (2003) 188(2):419-424.
46. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ et al: Prevention of recurrent preterm delivery by 17α-hydroxyprogesterone caproate. N Engl J Med (2003) 348(24):2379-2385.
47. Cole S, Smith R, Bisits A: Pharmacotherapy for preterm labour. Front Horm Res (2001) 27:279-307.